Plasma soluble triggering receptor expressed on myeloid cells-1 in Crohn's disease

Digestive and Liver Disease

Volumn 44, Issue 6, 2012, Pages 466-470

  Billioud, Vincent ^a,b   Gibot, Sébastien ^a,b   Massin, Frédéric ^c   Oussalah, Abderrahim ^a,b   Chevaux, Jean Baptiste ^a,b   Williet, Nicolas ^a,b   Bronowicki, Jean Pierre ^a,b   Bigard, Marc André ^a,b   Guéant, Jean Louis ^a,b   Peyrin Biroulet, Laurent ^a,b  

^a INSERM   (France)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

^c UNIVERSITÉ DE LORRAINE   (France)

Author keywords

Crohn's disease; Disease activity; Triggering receptor expressed on myeloid cells 1

Indexed keywords

ALBUMIN; AZATHIOPRINE; C REACTIVE PROTEIN; INFLIXIMAB; METHOTREXATE; SOLUBLE TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELL 1; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; UNCLASSIFIED DRUG;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROHN DISEASE; DIAGNOSTIC ACCURACY; DISEASE ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CROHN DISEASE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MEMBRANE GLYCOPROTEINS; METHOTREXATE; PROSPECTIVE STUDIES; RECEPTORS, IMMUNOLOGIC; SERUM ALBUMIN; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84860261151     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2012.01.005     Document Type: Article

References (24)

1. Dignass A., Van Assche G., Lindsay J.O., et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010, 4:28-62.
2. Vermeire S., Van Assche G., Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys. Gut 2006, 55:426-431.
3. Franchimont D. C-reactive protein: informative or misleading marker of Crohn's disease. Inflamm Bowel Dis 2007, 13:501-502.
4. Lewis J.D. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011, 140:1817-1826. e1812.
5. Van Assche G., Dignass A., Panes J., et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis 2010, 4:7-27.
6. Bruining D.H., Sandborn W.J. Do not assume symptoms indicate failure of anti-tumor necrosis factor therapy in Crohn's disease. Clin Gastroenterol Hepatol 2011, 9:395-399.
7. Li X., Conklin L., Alex P. New serological biomarkers of inflammatory bowel disease. World J Gastroenterol 2008, 14:5115-5124.
8. Klesney-Tait J., Turnbull I.R., Colonna M. The TREM receptor family and signal integration. Nat Immunol 2006, 7:1266-1273.
9. Derive M., Massin F., Gibot S. Triggering receptor expressed on myeloid cells-1 as a new therapeutic target during inflammatory diseases. Self Nonself 2010, 1:225-230.
10. Gibot S., Cravoisy A., Levy B., et al. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N Engl J Med 2004, 350:451-458.
11. Collins C.E., La D.T., Yang H.T., et al. Elevated synovial expression of triggering receptor expressed on myeloid cells 1 in patients with septic arthritis or rheumatoid arthritis. Ann Rheum Dis 2009, 68:1768-1774.
12. Kuai J., Gregory B., Hill A., et al. TREM-1 expression is increased in the synovium of rheumatoid arthritis patients and induces the expression of pro-inflammatory cytokines. Rheumatology (Oxford) 2009, 48:1352-1358.
13. Abraham C., Medzhitov R. Interactions between the host innate immune system and microbes in inflammatory bowel disease. Gastroenterology 2011, 140:1729-1737.
14. Schenk M., Bouchon A., Seibold F., Mueller C. TREM-1-expressing intestinal macrophages crucially amplify chronic inflammation in experimental colitis and inflammatory bowel diseases. J Clin Invest 2007, 117:3097-3106.
15. Park J.J., Cheon J.H., Kim B.Y., et al. Correlation of serum-soluble triggering receptor expressed on myeloid cells-1 with clinical disease activity in inflammatory bowel disease. Dig Dis Sci 2009, 54:1525-1531.
16. Tzivras M., Koussoulas V., Giamarellos-Bourboulis E.J., et al. Role of soluble triggering receptor expressed on myeloid cells in inflammatory bowel disease. World J Gastroenterol 2006, 12:3416-3419.
17. Jung Y.S., Kim S.W., Yoon J.Y., et al. Expression of a soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) correlates with clinical disease activity in intestinal Behcet's disease. Inflamm Bowel Dis 2011, 17:2130-2137.
18. Best W.R., Becktel J.M., Singleton J.W., Kern F. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976, 70:439-444.
19. Peyrin-Biroulet L., Oussalah A., Williet N., et al. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. Gut 2011, 60:930-936.
20. DeLong E.R., DeLong D.M., Clarke-Pearson D.L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988, 44:837-845.
21. Jung E.S., Kim S.W., Moon C.M., et al. Relationships between genetic polymorphisms of triggering receptor expressed on myeloid cells-1 and inflammatory bowel diseases in the Korean population. Life Sci 2011, 89:289-294.
22. Bleharski J.R., Kiessler V., Buonsanti C., et al. A role for triggering receptor expressed on myeloid cells-1 in host defense during the early-induced and adaptive phases of the immune response. J Immunol 2003, 170:3812-3818.
23. Jurgens M., Mahachie John J.M., Cleynen I., et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol 2011, 9:421-427. e421.
24. Sipponen T., Bjorkesten C.G., Farkkila M., et al. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scand J Gastroenterol 2010, 45:325-331.